# Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab

> **NCT06908070** · PHASE4 · RECRUITING · sponsor: **Idris Bahce** · enrollment: 38 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** Consolidation durvalumab

## Key facts

- **NCT ID:** NCT06908070
- **Lead sponsor:** Idris Bahce
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-17
- **Primary completion:** 2026-12-17
- **Final completion:** 2028-12-17
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908070, "Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06908070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*